APPLICATION OF THIOCTIC ACID IN NONALCOHOLIC STEATOHEPATITIS
- Authors: Russkikh A.V.1, Russkikh AV1
-
Affiliations:
- Issue: No 12 (2011)
- Pages: 87-92
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278947
- ID: 278947
Cite item
Full Text
Abstract
70% of patients with non-alcoholic steatohepatitis (NASH) experienced insulin-dependent diabetes mellitus, and the remaining 30% of patients experienced glucose intolerance in different periods of the disease. Decrease in the sensitivity of tissue receptors to insulin is a pathogenetic basis of NASH associated with heredity. Thioctic acid prevents the development of fatty liver disease and is a regulator of the number and functionality of membrane receptors, including insulin receptors. Ursodeoxycholic acid, metformin, and thioctic acid (Thiogamma) is well-studied, optimal and safe combination for the integrated pathogenetic treatment of NASH. Participation of thioctic acid in the antioxidant defense allows of conclusion about the advisability of administration of Thiogamma in all patients with elevated body mass index and insulin resistance for the prevention and treatment of hepatic steatosis and NASH.
References
- Яковенко Э.П., Григорьев П.Я., Агафонова Н.А., Яковенко А.В., Прянишникова А.С., Обуховский Б.И., Гусейнова Л.А., Мардарьева С.В., Рафаэлова М.А.. Метаболические заболевания печени: проблемы терапии // Фарматека, 2003. № 10(73). С. 47-52
- Brunt EM. Nonalcoholic steatohepatiatis. Semin Liver Dis 2004;4:3-20.
- Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2002;1:12-19.
- Roberts EA. Pediatric nonalcoholic fatty liver disease(NAFLD): A "growing" problem? J Hepatol 2007;46(6):1133-42.
- Mendez-Sanchez N, Arrese M, et al. Current concepts in patho-genesis of nonalcoholic fatty liver disease. Liver intern 2007;27(4):423-33.
- Donnelly KL, Smith CI, et al. Sources of fatty acids storet in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
- Pessayre D, Mansouri AM, Fromenty B. Nonalcoholic steatosis and steatohepatitis. Mitochondrial dysfunction in steatohepatitis. Am J Physiol 2002;282:193-99.
- Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev 2000;5(2):109-32.
- Arivazhagan P, Panneerselvam C. Effect of DL - alpha-lipoic acid on tissue nucleic acid contents in aged rats. Pharmacol Res 2000;42(3):223-26.
- Pierce RH, Campbell JS, et al. Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol 2000;157(1):221-36.
- Konrad T, Vicini P et al. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999; 22 (2): 280-7.
- Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296-301.
- Morita Y, Ueno T, Sasaki N, et al. Nateglinide improves non-alcoholic steatohepatitis with type 2 diabetes. J Hepatol 2006;44(2):699.
- Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134-46.
- Cai D,Yuan M, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005;11:183-90.
- Kelley D, Bray G, Xavier F, et al. Clinical efficacy of orlistat therapy in overweigh and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-41.
Supplementary files
